Showing results (61-70 of 331) with videos related to
Sort By:
Pageof 34
Cancers|January 23, 2024
Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-AnalysisNina B Curkovic, Kun Bai, Fei Ye, et al.Hematology/Oncology Clinics of North America|March 24, 2021
Advanced Melanoma: Resistance Mechanisms to Current TherapiesAlexandra M Haugh, April K S Salama, Douglas B JohnsonThe Oncologist|June 20, 2023
Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case SeriesRachel S Goodman, Seungyeon Jung, Jessica Quintos, et al.Oncoimmunology|November 11, 2017
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysisDaniel Y Wang, Fei Ye, Shilin Zhao, et al.The Oncologist|October 12, 2020
Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced MelanomaKaustav P Shah, Haocan Song, Fei Ye, et al.Current Opinion in Oncology|March 23, 2021
Supportive care for new cancer therapiesBernardo L Rapoport, Tim Cooksley, Douglas B Johnson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2014
Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemiaDouglas B Johnson, Keiran S M Smalley, Jeffrey A SosmanExpert Opinion on Biological Therapy|April 23, 2021
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapySelina K Wong, Kathryn E Beckermann, Douglas B Johnson, et al.Cancer|April 18, 2018
Melanoma: What do all the mutations mean?Elizabeth J Davis, Douglas B Johnson, Jeffrey A Sosman, et al.Cancers|October 16, 2025
Lack of Association Between Glucose Homeostasis and Immune Checkpoint Inhibitor Outcomes: A Retrospective Institutional ReviewJoy Justice, Hannah Burnette, Rebecca Irlmeier, et al.Pageof 34